Published in Ann N Y Acad Sci on February 10, 1967
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
A comparison of some cardiovascular properties of propranolol, MJ 1999 and quinidine in relation to their effects in hypertensive animals. Br J Pharmacol (1968) 1.29
Nature of the calcium dependent potassium leak induced by (+)-propranolol, and its possible relevance to the drug's antiarrhythmic effect. Br J Pharmacol (1972) 1.21
Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol (1971) 1.04
Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest (1990) 0.90
Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs. Br J Pharmacol (1986) 0.79
Anti-arrhythmic, local anaesthetic, and adrenergic blocking activity of some beta-receptor antagonists. Br J Pharmacol (1969) 0.77
Effect of -adrenoceptor blocking agents on poststimulatory atrial flutter in the dog, with observations on the participation of adrenergic mechanisms in this experimental arrhythmia. Br J Pharmacol (1972) 0.75
Beta-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity. Br J Clin Pharmacol (1982) 0.75
Cardiovascular effects of acebutolol following coronary artery occlusion and reperfusion in anaesthetized dog. Br J Pharmacol (1978) 0.75
Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation (1983) 4.01
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest (1988) 2.46
Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res (1984) 2.44
Myocardial protection with preconditioning. Circulation (1990) 1.83
The role of nicotine as a determinant of cigarette smoking frequency in man with observations of certain cardiovascular effects associated with the tobacco alkaloid. Clin Pharmacol Ther (1968) 1.67
Cardiac actions of glucagon. Circ Res (1968) 1.64
Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol (1986) 1.61
Mechanisms of myocardial reperfusion injury. Ann Thorac Surg (1999) 1.47
Free radicals and myocardial ischemia and reperfusion injury. J Lab Clin Med (1987) 1.45
High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol (1993) 1.44
The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Br J Clin Pharmacol (1995) 1.44
Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke (1994) 1.43
Effect of hypoxia and reoxygenation on the isolated rabbit heart determined by monoclonal antimyosin antibody uptake. Cardiovasc Res (1993) 1.37
Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J (1986) 1.31
Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res (1980) 1.22
The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. Circulation (1982) 1.21
Free radicals and myocardial injury: pharmacologic implications. Circulation (1986) 1.19
The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res (1994) 1.19
Electrophysiologic and antiarrhythmic effects of phentolamine in experimental coronary artery occlusion and reperfusion in the dog. J Cardiovasc Pharmacol (1980) 1.18
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation (2001) 1.16
Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation (1990) 1.15
Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res (1998) 1.12
The effect of diltiazem on coronary thrombosis in the conscious canine. Eur J Pharmacol (1982) 1.10
Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion. Circ Res (1988) 1.09
The pharmacology of beta-adrenergic blocking agents. Prog Cardiovasc Dis (1969) 1.09
Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res (1987) 1.06
Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res (1994) 1.05
Deficiency of leukocyte surface glycoproteins Mo1, LFA-1, and Leu M5 in a dog with recurrent bacterial infections: an animal model. Blood (1987) 1.05
The independent effects of oxygen radical scavengers on canine infarct size. Reduction by superoxide dismutase but not catalase. Circ Res (1985) 1.05
Free radicals and ischemic tissue injury. Trends Pharmacol Sci (1990) 1.05
Effects of propranolol and its stereoisomers upon coronary vascular resistance. Circ Res (1967) 1.03
O2 free radical-mediated myocardial and vascular dysfunction. Am J Physiol (1986) 1.03
Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J (1987) 1.00
Reduction of the size of infarction by allopurinol in the ischemic-reperfused canine heart. Circulation (1986) 0.99
Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol (1994) 0.99
Free radicals in ischemic myocardial injury. J Free Radic Biol Med (1985) 0.98
Effect of BW755C in an occlusion-reperfusion model of ischemic myocardial injury. Am Heart J (1983) 0.98
Protective effects of N-2-mercaptopropionyl glycine against myocardial reperfusion injury after neutrophil depletion in the dog: evidence for the role of intracellular-derived free radicals. Circulation (1986) 0.98
Inability of methylprednisolone sodium succinate to decrease infarct size or preserve enzyme activity measured 24 hours after coronary occlusion in the dog. Circulation (1977) 0.97
Electrolysis-induced myocardial dysfunction. A novel method for the study of free radical mediated tissue injury. J Pharmacol Methods (1986) 0.97
The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions (1991) 0.97
Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation (1990) 0.96
Free radical scavengers in myocardial ischemia. Fed Proc (1987) 0.96
Protective effects of beta-adrenergic blockade in isolated ischemic hearts. Eur J Pharmacol (1980) 0.96
Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol (1990) 0.95
The positive inotropic action of insulin in the canine heart. Eur J Pharmacol (1972) 0.94
Changes in myocardial threshold. Physiologic and pharmacologic factors in patients with implanted pacemakers. Am Heart J (1967) 0.94
Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death. Am J Cardiol (1982) 0.93
Heat shock proteins and the ischemic heart. An endogenous protective mechanism. Circulation (1993) 0.93
Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J Cardiovasc Pharmacol (1982) 0.93
Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart. Circ Res (1988) 0.93
Ischemic changes in the canine heart as affected by the dimethyl quaternary analog of propranolol, UM-272 (SC-27761). J Pharmacol Exp Ther (1976) 0.93
Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation (1994) 0.93
Canine myocardial reperfusion injury: protection by a free radical scavenger, N-2-mercaptopropionyl glycine. J Cardiovasc Pharmacol (1986) 0.93
Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J Mol Cell Cardiol (1998) 0.92
Myocardial threshold in patients with artificial pacemakers. Am J Cardiol (1966) 0.92
Protective effects of the SOD-mimetic SC-52608 against ischemia/reperfusion damage in the rabbit isolated heart. J Mol Cell Cardiol (1994) 0.92
Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hours of regional ischemia and reperfusion: a demonstration of myocardial salvage. Circ Res (1989) 0.92
Myocardial infarct quantification in the dog by single photon emission computed tomography. Circulation (1978) 0.91
The antiarrhythmic properties of ICI 46037, a quaternary analog of propranolol. J Pharmacol Exp Ther (1968) 0.90
The nitroglycerin polymer gel matrix system: a new method for administering nitroglycerin evaluated with plasma nitroglycerin levels. J Cardiovasc Pharmacol (1982) 0.90
Propranolol (Inderal) in experimentally-induced cardiac arrhythmias. Can J Physiol Pharmacol (1966) 0.90
Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J Immunol (1993) 0.90
Platelet-activating factor and the release of a platelet-derived coronary artery vasodilator substance in the canine. Circ Res (1986) 0.89
Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res (1994) 0.89
Postinfarction sudden death: significance of inducible ventricular tachycardia and infarct size in a conscious canine model. Am Heart J (1985) 0.89
Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol (1994) 0.89
The cardiac beta-adrenergic receptor blocking actions of propranolol and its stereoisomers. Life Sci (1967) 0.88
Acute cocaine exposure up-regulates complement expression in rabbit heart. J Pharmacol Exp Ther (2000) 0.88
Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation (1990) 0.87
Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog. Circulation (1981) 0.87
Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation (1994) 0.87
Free radicals upregulate complement expression in rabbit isolated heart. Am J Physiol Heart Circ Physiol (2000) 0.87
Reperfusion injury after myocardial infarction: the role of free radicals and the inflammatory response. Clin Biochem (1993) 0.87
Effect of 4-(2-hydroxy-3-isopropylaminopropoxy) acetanilide (AY 21,011) on the myocardial and coronary vascular responses to adrenergic stimulation. J Pharmacol Exp Ther (1971) 0.87
Hypothyroidism renders protection against lethal ventricular arrhythmias in a conscious canine model of sudden death. J Cardiovasc Pharmacol (1991) 0.87
Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res (1992) 0.87
The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog. J Pharmacol Exp Ther (1980) 0.87
The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther (1998) 0.87
Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ Res (1968) 0.86
The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant Proc (1999) 0.86
Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J Pharmacol Exp Ther (1988) 0.86
Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. J Cardiovasc Pharmacol (1985) 0.86
The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther (1991) 0.86
Disopyramide plasma and myocardial tissue concentrations as they relate to antiarrhythmic activity. J Cardiovasc Pharmacol (1980) 0.85
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol (1987) 0.85
Platelet depletion in experimental myocardial infarction. Basic Res Cardiol (1985) 0.85
Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart. J Mol Cell Cardiol (1988) 0.85
Role of neutrophils in ischemic heart disease: pathophysiologic role in myocardial ischemia and coronary artery reperfusion. Cardiovasc Clin (1987) 0.84
Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics. J Pharmacol Exp Ther (1998) 0.84
Alpha-adrenergic influences in canine ischemic sudden death: effects of alpha 1-adrenoceptor blockade with prazosin. J Cardiovasc Pharmacol (1987) 0.84
Modulation of myoglobin-H2O2-mediated peroxidation reactions by sulfhydryl compounds. Lab Invest (1988) 0.84
Lanthanum staining of coronary microvascular endothelium: effects of ischemia reperfusion, propranolol, and atenolol. Microvasc Res (1981) 0.84
Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res (1995) 0.83
Electrophysiologic actions and antifibrillatory efficacy of subacute left stellectomy in a conscious, post-infarction canine model of ischemic ventricular fibrillation. Int J Cardiol (1989) 0.83